Company intelligence / Profile preview

IBEX Medical Systems

Ownership: Private
Employees: ~40
Development stage: Commercial

Overview

Ibex’s AI-powered Galen™ platform has demonstrated near-perfect concordance with expert pathologists for detection and grading of multiple cancers. Clinical studies have validated its accuracy for diagnosis of breast and prostate cancers—including subtyping and grading—supporting improved diagnostic confidence and workflow efficiency. The technology has received FDA Breakthrough Device Designation and CE mark approval.

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapyArtificial intelligence-based diagnostics platform
Industry: Pathology

Partnerships

Roche – partnership to integrate Ibex’s AI algorithms into Roche’s NAVIFY Digital Pathology software suite.

Beyond the preview

Go deeper on IBEX Medical Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBEX Medical Systems.

Explore the full profile